摘要
目的:探讨患者血清YKL-40蛋白水平与非肌层浸润性膀胱癌(non muscle-invasive bladder cancer,NMIBC)复发的临床关系。方法:选取76例NMIBC患者,其中34例为术后随访两年内确诊复发患者、42例为术后随访两年未见复发患者,及健康对照组31例,采取清晨血清样本,采用酶联接免疫吸附剂测定法(ELISA)检测患者血清中YKL-40水平。结果:NMIBC患者血清YKL-40水平显著高于健康对照组(P<0.001),同时,NMIBC复发组患者血清YKL-40水平高于非复发组(P=0.001)。结论:血清YKL-40蛋白水平在非肌层浸润性膀胱癌复发中有着较高的临床诊断价值,可作为监测患者术后复发的一种新分子标志物,为患者术后相关后续治疗提供参考。
Objective: The aim of this study was to further understand the correlation between serum YKL-40 protein level and recurrence of non muscle-invasive bladder cancer (NMIBC). Methods: Totally, 76 patients of NMIBC and 31 healthy volunteers were recruited in this study. After two years follow-up, 34 patients were found with recurrence by cystoscope. Serum YKL-40 protein levels of all these patients were analysed by using Enzyme- linked immunosorbent assay (ELISA) methods. Data analyses and ROC curve were performed in SPSS. All values are two tailed. Results: Serum YKL-40 protein levels were significantly higher in patients with bladder cancercompared with controls (P〈0.001). Serum YKL-40 protein levels were found to be higher in patients with recurrent NMIBC compared with patients with non recurrent bladder cancer (P=0.001). Conclusion: Serum YKL-40 protein could be a reliable molecular marker for diagnosis of recurrence of NMIBC. Serum YKL-40 protein level could provide a good value of guide for postoperative treatment.
出处
《临床与病理杂志》
CAS
2015年第4期598-602,共5页
Journal of Clinical and Pathological Research
基金
上海市自然科学基金面上项目(14ZR1432300)~~